Skip to content

Study on the Clinical Efficacy and Mechanism of Guzhi Syrup for Residual Dizziness After Repositioning in Elderly Patients with Senile Osteoporosis and BPPV

Study on the Clinical Efficacy and Mechanism of Guzhi Syrup for Residual Dizziness After Repositioning in Elderly Patients with Senile Osteoporosis and BPPV

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000573
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis associated with benign paroxysmal positional vertigo (BPPV)

Interventions

Treatment group:Guzhi Syrup combined with Calcium Carbonate D3 Tablets and Calcitriol Soft Capsules.
Control Group:Calcium Carbonate D3 Tablets and Calcitriol Soft Capsules.

Sponsors

Xi'an Fifth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age between 60-80 years old; (2) Confirmed diagnosis of idiopathic BPPV with successful manual repositioning (negative Dix-Hallpike or Roll Test) after 1-2 attempts; (3) Meets diagnostic criteria for primary osteoporosis (-3.0 <= T-score <= -2.0); (4) Meets the diagnostic criteria for kidney deficiency and blood stasis pattern in traditional Chinese medicine; (5) Able to complete questionnaires and examinations; (6) Voluntarily participates and signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Secondary BPPV (caused by trauma, otitis media, Meniere's disease, etc.) or central vertigo; (2) Severe cervical spondylosis or fresh lumbar compression fractures that affect the implementation of treatment plans; (3) Severe cardiovascular and cerebrovascular diseases (including severe arrhythmia, acute cerebral infarction/ cerebral hemorrhage); (4) Severe hepatic or renal insufficiency, rheumatoid arthritis, hyperparathyroidism, or other diseases affecting bone metabolism; (5) Drug allergy, or recent use of medications affecting bone metabolism or cerebral vascular function; (6) Diabetic patients or patients with elevated blood glucose; (7) Unable to cooperate with cranial MRI, TCD, or bone density examinations.

Design outcomes

Primary

MeasureTime frame
Incidence rate of RD;Vertigo Disability Scale;

Secondary

MeasureTime frame
TCM Syndrome Score;Bone Density;Cerebral vascular reactivity;Anterior circulation cerebral hemodynamics;Safety Index;Residual dizziness symptom changes;Serum bone metabolism status;

Countries

China

Contacts

Public ContactYan Jun

Xi'an Fifth Hospital

263329976@qq.com029-84696418

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026